Renal Cell Carcinoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for renal cell carcinoma. 30 active patents protecting 4 drugs from 2+ originators. First major cliff: 2026. Daily refresh.

4
Approved drugs
30
Active US patents
63/100
Avg vulnerability
$600M
Annual revenue covered

Originators in Renal Cell Carcinoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 26 patents Novartis 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating renal cell carcinoma. Each bar = one year. Y-axis scaled to peak year (8 patents).

1
26
4
28
1
29
3
30
2
31
2
32
8
35
4
36
4
37
1
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Inlyta
Axitinib
 Pfizer 16 59 — 2030-12-14
Rapamune
sirolimus
 Pfizer 7 58 — 2029-02-14
Afinitor
everolimus
 Novartis 4 70 $600M 2028-07-01
Torisel
temsirolimus
 Pfizer 3 66 — 2026-07-20

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8026276 Torisel other 80 2026-07-20
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01
8911786 Rapamune method of use 75 2029-02-14
12534530 Inlyta method of use 75 2035-02-03
12534530 Inlyta method of use 75 2035-02-03
12133844 Rapamune method of use 75 2036-06-29
8791097 Torisel method of use 73 2032-05-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8791140 Inlyta composition of matter 15 2030-12-14
8791140 Inlyta composition of matter 15 2030-12-14
10705070 Rapamune formulation 42 2036-03-05
10206887 Rapamune formulation 48 2030-04-15
11497737 Rapamune formulation 50 2040-10-28
12061183 Rapamune formulation 55 2036-03-05
10869924 Inlyta other 62 2037-07-12
10869924 Inlyta other 62 2037-07-12
10869924 Inlyta method of use 62 2037-01-12
10869924 Inlyta method of use 62 2037-01-12

Related